CeriBell (NASDAQ:CBLL - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08), Zacks reports. The company had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. CeriBell updated its FY 2025 guidance to EPS.
CeriBell Stock Performance
Shares of NASDAQ CBLL traded down $0.52 during midday trading on Friday, reaching $23.24. The stock had a trading volume of 375,746 shares, compared to its average volume of 193,006. CeriBell has a twelve month low of $18.69 and a twelve month high of $32.75. The firm has a 50 day simple moving average of $23.34.
Analysts Set New Price Targets
A number of brokerages have recently commented on CBLL. JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They set an "overweight" rating and a $32.00 price target on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday. William Blair started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an "outperform" rating on the stock. Canaccord Genuity Group started coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $30.00 price target on the stock. Finally, TD Cowen lifted their price target on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $32.60.
Get Our Latest Research Report on CBLL
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
